BioVersys
Basel
About BioVersys
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $138.8M
- Funding stage: IPO
- Last round: Grant (Nov 2025)
- Ticker: six:BIOV
- Website: bioversys.com
- Phone: +41 78 670 40 85
Industries & Categories
Biopharma, Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bioversys-80910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.